Anti-cancer drug-resistant metastatic cancer, we've found a cure
Apr 07, 2025
A new substance has been developed to reduce the side effects of existing heart diseases while suppressing target proteins for the treatment of metastatic cancer.
A research team led by Professor Park Ki-cheong of Yonsei University's School of Surgery and Professor Kim Seok-mo of thyroid endocrine surgery at Gangnam Severance Hospital announced on the 7th that they have developed a new substance that can reduce the side effects of heart disease as well as confirming that the growth of cancer cells is suppressed when SERCA protein is blocked in cells.
The findings were published in the latest issue of the British Journal of Pharmacy (IF 6.8).
Metastatic cancer cells are prone to resistance to existing anticancer drugs. When the function of SERCA protein was suppressed in metastatic cancer, the anticancer treatment effect was confirmed to increase, and SERCA protein suppression became a hot topic for metastatic cancer treatment. However, the development was suspended due to the side effects of heart disease.
SERCA protein is composed of three subtypes, SERCA 1, 2, and 3, of which SERCA 2 is responsible for the relaxation and contraction of the heart muscle. Because previously developed SERCA protein inhibitors inhibit SERCA protein itself regardless of subtype, side effects of heart disease could not be avoided.
The research team has developed two new substances, CKP 1 and 2, which are selective inhibitors to target only SERCA 1, which affects increased resistance to anticancer drugs, except SERCA 2. The drug development collaboration was conducted with CKP Therapeutics, a Boston-based company in the United States.
The research team compared the therapeutic effects of the two new substances developed with the existing standard anticancer drugs sorafenib and renbatinib. Metastatic cancer cells showing resistance were isolated from tissues of cancer patients who had metastasized while receiving treatment with existing standard anticancer drugs, and a mouse model was created using the increased SERCA1 protein.
In the comparative study conducted, there was no anticancer effect in the area where sorafenib and renbatinib were administered, but in the group where two new CKP 1 and 2 substances were co-administered with sorafenib or renbatinib, tumor growth was significantly suppressed and there were no side effects of heart disease.
Then, in order to further confirm the side effects of heart disease, two new substances, Tapsigargin and CKP 1, 2, which are existing SERCA inhibitors, were administered to normal mice and compared. As a result, 30% of the individuals died in the Tapsigargin-administered mice, but there were no deaths in the CKP 1 and 2 drug-administered groups.
Based on these results, the research team said, CKP 1 and 2 selectively impede only SERCA 1's function and leave SERCA 2's function intact, eliminating side effects from heart disease.
Professor Kim Seok-mo said, `Through this study, we have developed a drug that can not only treat metastatic cancer that is resistant to existing anticancer drugs but also catch side effects of heart disease.'
Professor Park Ki-cheong said, `We will continue to provide treatments for incurable cancer in the future.' `As the results of this study have even obtained domestic and foreign patents, it will lead to follow-up studies for future clinical research and new drug development.'
A research team led by Professor Park Ki-cheong of Yonsei University's School of Surgery and Professor Kim Seok-mo of thyroid endocrine surgery at Gangnam Severance Hospital announced on the 7th that they have developed a new substance that can reduce the side effects of heart disease as well as confirming that the growth of cancer cells is suppressed when SERCA protein is blocked in cells.
The findings were published in the latest issue of the British Journal of Pharmacy (IF 6.8).
Metastatic cancer cells are prone to resistance to existing anticancer drugs. When the function of SERCA protein was suppressed in metastatic cancer, the anticancer treatment effect was confirmed to increase, and SERCA protein suppression became a hot topic for metastatic cancer treatment. However, the development was suspended due to the side effects of heart disease.
SERCA protein is composed of three subtypes, SERCA 1, 2, and 3, of which SERCA 2 is responsible for the relaxation and contraction of the heart muscle. Because previously developed SERCA protein inhibitors inhibit SERCA protein itself regardless of subtype, side effects of heart disease could not be avoided.
The research team has developed two new substances, CKP 1 and 2, which are selective inhibitors to target only SERCA 1, which affects increased resistance to anticancer drugs, except SERCA 2. The drug development collaboration was conducted with CKP Therapeutics, a Boston-based company in the United States.
The research team compared the therapeutic effects of the two new substances developed with the existing standard anticancer drugs sorafenib and renbatinib. Metastatic cancer cells showing resistance were isolated from tissues of cancer patients who had metastasized while receiving treatment with existing standard anticancer drugs, and a mouse model was created using the increased SERCA1 protein.
In the comparative study conducted, there was no anticancer effect in the area where sorafenib and renbatinib were administered, but in the group where two new CKP 1 and 2 substances were co-administered with sorafenib or renbatinib, tumor growth was significantly suppressed and there were no side effects of heart disease.
Then, in order to further confirm the side effects of heart disease, two new substances, Tapsigargin and CKP 1, 2, which are existing SERCA inhibitors, were administered to normal mice and compared. As a result, 30% of the individuals died in the Tapsigargin-administered mice, but there were no deaths in the CKP 1 and 2 drug-administered groups.
Based on these results, the research team said, CKP 1 and 2 selectively impede only SERCA 1's function and leave SERCA 2's function intact, eliminating side effects from heart disease.
Professor Kim Seok-mo said, `Through this study, we have developed a drug that can not only treat metastatic cancer that is resistant to existing anticancer drugs but also catch side effects of heart disease.'
Professor Park Ki-cheong said, `We will continue to provide treatments for incurable cancer in the future.' `As the results of this study have even obtained domestic and foreign patents, it will lead to follow-up studies for future clinical research and new drug development.'
|
This article was translated by Naver AI translator.
